MedPath

AHS Cancer Control Alberta

🇨🇦Canada
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

183

Active:8
Completed:73

Trial Phases

5 Phases

Early Phase 1:4
Phase 1:30
Phase 2:65
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (140 trials with phase data)• Click on a phase to view related trials

Phase 2
65 (46.4%)
Not Applicable
34 (24.3%)
Phase 1
30 (21.4%)
Phase 3
7 (5.0%)
Early Phase 1
4 (2.9%)

This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer

Phase 2
Not yet recruiting
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
Drug: Scheduling of the time of pembrolizumab infusions
First Posted Date
2025-03-18
Last Posted Date
2025-03-18
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
58
Registration Number
NCT06882174

Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis

Phase 2
Not yet recruiting
Conditions
Pneumonitis
Immune-related Adverse Event
Interventions
Other: Arm 1- Usual care
Drug: Arm 2- Budesonide (Pulmicort® Turbuhaler®) + Usual care
First Posted Date
2025-03-06
Last Posted Date
2025-03-06
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
94
Registration Number
NCT06860542

GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma

Early Phase 1
Completed
Conditions
Alveolar Soft Part Sarcoma
Interventions
First Posted Date
2025-02-14
Last Posted Date
2025-07-23
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
1
Registration Number
NCT06827886
Locations
🇨🇦

Tom Baker Cancer Centre/Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Canada

COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer

Phase 2
Not yet recruiting
Conditions
Advanced Differentiated Thyroid Gland Carcinoma
Interventions
Drug: Levothyroxine Oral Tablet [Synthroid]
First Posted Date
2025-01-24
Last Posted Date
2025-02-04
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
70
Registration Number
NCT06790589

GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient with Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)

Early Phase 1
Not yet recruiting
Conditions
Alveolar Soft Part Sarcoma
Interventions
First Posted Date
2025-01-23
Last Posted Date
2025-01-23
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
1
Registration Number
NCT06789081
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 37
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.